Neoadjuvant HER2+ Articles

Landmark Approvals Lead to Continual Progress in HER2+ Breast Cancer
Cindy Osborne, MD, highlights the many advances that have been made in the treatment paradigms of locally advanced and metastatic HER2-positive breast cancer.
HER2+ Breast Cancer Paradigm Evolving With Practice-Changing New Options
Mark D. Pegram, MD, highlights data from pivotal studies that have helped to shape the current landscape of HER2-positive breast cancer and sheds light on emerging agents that are showing promise in the pipeline.
[Fam]-Trastuzumab Deruxtecan Accelerates Through HER2+ Breast Cancer Pipeline
An accelerated filing of a biologics license application is planned for [fam-] trastuzumab deruxtecan (DS-8201) as a treatment for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine.
HER2+ Breast Cancer Paradigm Slated to Expand With Novel Therapies
Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.
Hurvitz Highlights Emerging Agents for Heavily Pretreated HER2+ Breast Cancer
Sara A. Hurvitz, MD, discusses recent updates in the paradigm and promising therapeutic strategies on the horizon for patients with HER2-positive metastatic breast cancer.
Novel Agents May Change Paradigm for Advanced HER2+ Breast Cancer
The treatment of patients with advanced HER2-positive breast cancer could be reshaped in the next several years as clinical trials of several exciting new drugs begin to yield results.
Novel Agents, Approaches Drive Progress in HER2+ Breast Cancer
Erika P. Hamilton, MD, shares insight on the management of patients with HER2-positive breast cancer and strategies aimed at targeting treatment resistance and toxicity.
FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer
The FDA has approved subcutaneous use of trastuzumab and hyaluronidase-oysk injection in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, in combination with paclitaxel in patients with metastatic HER2-positive breast cancer as a frontline treatment, and alone for patients with metastatic disease who have received at least 1 prior chemotherapy regimen
Options Shift Paradigm of Locally Advanced HER2+ Breast Cancer
Theresa Shao, MD, discusses the neoadjuvant and adjuvant findings with pertuzumab as well as the adjuvant use of neratinib in patients with locally advanced HER2-positive breast cancer.
HER2+ Breast Cancer Treatment Evolving With New Data, Novel Agents
Erika P. Hamilton, MD, reflects on the latest data in HER2-positive breast cancer and additional therapies moving through the pipeline.
Publication Bottom Border
Border Publication